Gilead Sciences, Inc. (GIS.F)
| Previous close | 63.55 |
| Open | 63.57 |
| Bid | 63.44 x 50000 |
| Ask | 63.56 x 50000 |
| Day's range | 63.39 - 63.69 |
| 52-week range | 57.58 - 80.08 |
| Volume | |
| Avg. volume | 566 |
| Market cap | 79.172B |
| Beta (5Y monthly) | 0.22 |
| PE ratio (TTM) | 186.44 |
| EPS (TTM) | 0.34 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | 2.88 (4.54%) |
| Ex-dividend date | 14 June 2024 |
| 1y target est | N/A |
Simply Wall St.Should You Be Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
GuruFocus.comInsider Sale: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)
Following this sale, the insider now owns 96,380 shares of Gilead Sciences Inc. Gilead Sciences Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company's portfolio includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
Insider MonkeyShould You Hold Gilead Sciences (GILD)?
Parnassus Investments, an investment management company, released the “Parnassus Value Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) appreciated 10.17% outperforming the Russell 1000 Value Index’s 8.99%. Stock selection in the Information Technology and Communication Services sectors was the […]
